Coloplast A/S
Coloplast A/S - Transactions in connection with share buy-back programme, week 10
As mentioned in Announcement no. 02/2021 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.
The programme commenced on 22 February 2021 and is expected to end by 23 August 2021.
The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.
The following transactions have been executed during the period 8 – 12 March 2021:
Date | Number of shares | Average purchase price, DKK | Transaction value, DKK |
08 March 2021 | 300 | 873.04 | 261,912 |
09 March 2021 | 250 | 880.19 | 220,048 |
10 March 2021 | 300 | 900.08 | 270,024 |
11 March 2021 | 400 | 910.37 | 364,148 |
12 March 2021 | 400 | 913.66 | 365,464 |
Accumulated until now under the programme | 56,050 | 908.24 | 50,906,832 |
Henceforth, Coloplast owns 3,091,947 treasury B shares of DKK 1 equal to 1.43% of the company’s total share capital.
An overview showing the transaction data for the period 8 – 12 March 2021 is enclosed.
Kind regards,
Investor Relations
Coloplast A/S
Tel. +45 4911 1800
For further information, please contact
Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 /+45 4911 3376
Email: dkebj@coloplast.com
Aleksandra Dimovska
Sr. Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com
Press and the media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com
Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917
Website
www.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-03.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
Attachments
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Boyden15.4.2021 03:24:01 CEST | Press release
Record year for Boyden Denmark in 2020
Boyden15.4.2021 03:23:51 CEST | Pressemeddelelse
Rekordår for det nye Boyden-team i Danmark
TigerGraph, Inc.8.4.2021 15:01:29 CEST | Press release
TigerGraph’s Graph + AI Summit 2021 to Feature 40+ Sessions, Live Workshops and Speakers from JPMorgan Chase, NewDay, Pinterest, Jaguar Land Rover and More
Agillic A/S7.4.2021 09:01:28 CEST | Press release
Agillic launches a new fast and advanced SMS editor to help clients deliver personalised SMS experiences
TigerGraph, Inc.30.3.2021 15:29:56 CEST | Press release
Technical University of Denmark uses TigerGraph to help find more effective treatments for acute lymphoblastic leukemia
Møns Bank A/S26.3.2021 07:03:33 CET | Pressemeddelelse
Indkaldelse til ekstraordinær generalforsamling 19. april 2021
Sika AG26.3.2021 07:02:09 CET | Press release
SIKA ACQUIRES FLOORING ADHESIVES BUSINESS IN THE USA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom